Asterivir

Asterivir's team has been working for ten years at EPFL on the development of broad-spectrum antiviral drugs capable of being effective not only against existing viruses but also against emerging viruses. The technology has proven to be effective in vitro across a wide range of viruses and has also proven to be effective in vivo against Influenza, RSV, and HSV2. More recently, we found that our molecules developed against influenza have a good SARS-CoV-2 inhibitory response.

We are now establishing Asterivir, as a spin-off from EPFL, to develop a molecule described here as a drug against SARS-CoV-2 and against future influenza and / or coronavirus pandemics that may follow.